双苄基异喹啉化合物Ys-96与阿霉素或长春新碱联合用药对体外培养人癌细胞的抗癌增效作用  

Synergistic Interaction Between Ys-96,A Bisbenzylisoquinoline Compound Derived from Stephania tetrandra ,and Adriamycin or Vincristine Against Human Cancer Cell Lines in Vitro

作　　者：叶祖光[1] 孙爱续[1] 李春英[1] 薛宝云[1] 梁爱华[1] 王金华[1] 王智民[1] 仝燕[1] 冯浩[1] 

机构地区：[1]中国中医研究院中药研究所,北京100700

出　　处：《中国中药杂志》1999年第9期556-559,共4页China Journal of Chinese Materia Medica

基　　金：国家自然科学基金!No.3 95 70 871

摘　　要：目的:研究双苄基异喹啉化合物Ys96与阿霉素或长春新碱联合用药对体外培养人癌细胞系MCF7和KB的抗癌增效作用。方法:在体外培养的敏感株人乳腺癌细胞MCF7及其阿霉素耐药株MCF7/Adr和敏感株人口腔粘膜上皮样癌细胞KB及其长春新碱耐药株KBv200的体外试验系统中,采用Berenbaum所报道的评价二药相互作用性质的试验方法,对源于中药汉防己的双苄基异喹啉化合物Ys96与阿霉素或长春新碱联合用药的抗癌作用进行了研究。结果:3种不同比例混合的Ys96和阿霉素或长春新碱联合用药对敏感株MCF7或KB以及耐药株MCF7/Adr或KBv200的IC50分数值之和(SFIC)均小于1.0,而且所有联合用药的等效曲线形态均为凹型。结论:Ys96与阿霉素或长春新碱联合用药对上述体外培养的人癌细胞具有抗癌增效作用。Objective:To study in vitro the anticancer interaction between Ys 96, a bisbenzylisoquinoline compound derived from Stephania tetrandra ,and adriamycin or vincristine against human cancer cell lines.Method:Using human breast cancer cell MCF 7 and its adriamycin resistant cell line MCF 7/Adr, and human nasopharyngeal cancer cell KB and its vincristine resistant cell line KBv200 in an in vitro system,anticancer interaction between Ys 96 and adriamycin or vincristine was evaluated with a method reported by Berenbaum.Result:The SFIC values (sum of fractional inhibitory concentration)of the combinations with 3 different ratios between Ys 96 and adriamycin or vincristine were markedly less than 1.0, and the shapes of all the isobologram curves were concave.Conclusion:The synergistic interaction between Ys 96 and adriamycin or vincristine against the above human cancer cell lines was positively observed in vitro.

关 键 词：双苄基异喹啉 阿霉素 长春新碱 抗癌增效 

分 类 号：R979.1[医药卫生—药品]